- Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
- Regentis’ GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
- A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis’ preparation for commercial scale-up as clinical and regulatory milestones approach
Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.
Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional treatment pathways.
The Limitations of Today’s Standard
For active patients with focal cartilage damage, current treatment options often involve trade-offs.
Microfracture remains widely used because it is relatively straightforward and familiar to orthopedic surgeons, but the tissue it produces is fibrocartilage rather than true hyaline cartilage, making durability a persistent concern. Cell-based procedures offer a more biologically sophisticated approach, but typically require an initial biopsy, weeks of laboratory cell expansion, and a second surgical procedure for implantation. Costs for those approaches can range from approximately $38,000 to $45,000 per case.
Other repair methods may involve harvesting plugs from healthy bone and cartilage and requiring two surgeries, introducing additional trauma through surgical complexity and donor-site concerns. No currently available cartilage repair solution combines off-the-shelf availability, a single short procedure, regenerative cartilage restoration, and long-term durability in a single treatment approach.
A Different Regenerative Model
GelrinC(R) represents a fundamentally different regenerative approach designed to simplify one of orthopedics’ most complex treatment categories.
The product is an acellular hydrogel composed of polyethylene glycol and denatured fibrinogen, delivered into a cartilage defect in liquid form and then cured into a solid degradable hydrogel implant using ultraviolet light. The implant is designed to gradually resorb in a synchronized manner as native surrounding cells migrate inward, supporting regeneration of hyaline-like cartilage tissue over time.
From a practical standpoint, the workflow is materially simpler than cell-based alternatives. The procedure takes approximately 10 minutes, can be performed using open or minimally invasive techniques, and does not require tissue harvesting, cell culturing, or delayed reimplantation. Surgeons use the product at the point of care rather than coordinating a multi-step treatment pathway.
That combination of procedural simplicity and regenerative intent is central to the company’s commercial thesis.
Clinical Progress and Commercial Preparation
Clinical data have provided the early foundation for that thesis.
In a Phase II study involving 56 patients across Northern Europe and Israel, GelrinC(R) demonstrated statistically significant improvement in its primary endpoint measuring KOOS outcomes at 24 months. GelrinC(R) treatment resulted in 100% greater overall KOOS (Knee Injury and Osteoarthritis Outcome Score) clinical outcomes compared to microfracture controls, including significant improvements in pain, function, and patient recovery measures, compared to microfracture controls. In parallel, quantitative MOCART imaging scores – a validated, FDA-accepted MRI assessment method – suggested near-complete structural repair and among the highest reported cartilage repair outcomes in the field. No serious adverse events were reported.
Those results supported CE Mark marketing approval in Europe, where Regentis is now actively building a commercialization infrastructure and physician adoption pathways ahead of planned market entry.
In April, the company announced a collaboration with Humanitas Research Hospital in Milan, one of Europe’s leading orthopedic and sports medicine centers, alongside internationally recognized cartilage regeneration expert Prof. Elizaveta Kon. The initiative is part of Regentis’ broader strategy to establish a European Centers of Excellence network designed to support surgeon education, clinical guidance, and large-scale physician adoption ahead of commercialization.
Commercial readiness is also showing up operationally. In March, Regentis announced a newly developed solvent-free manufacturing process that more than quadruples GelrinC(R) production yield per batch. Beyond improving production economics, the manufacturing advancement suggests active preparation for broader commercial deployment.
The U.S. Regulatory Path
In the United States, GelrinC(R) is advancing through a pivotal FDA study under an Investigational Device Exemption pathway.
The study uses a single-arm design with historical microfracture controls previously accepted by regulators, rather than a concurrent randomized comparator arm. Enrollment is targeted at 80 patients, with more than half already recruited and treated according to company disclosures.
If enrollment proceeds as expected, the program could move toward PMA submission in late 2027.
Orthopedic innovation often moves slowly, particularly in categories where legacy procedures remain entrenched despite well-understood limitations. Knee cartilage repair appears to be one of those markets. Regentis is pursuing an opportunity built around procedural simplicity, regenerative intent, and commercial practicality in a category where those elements have rarely aligned in a single product.
For more information, visit the company’s website at www.Regentis.co.il.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
